CD4 and neoplasm: Immune responses included sustained mKRAS-specific CD4+ and CD8+ T cell subsets exhibiting favorable effector cytokine function, cytotoxic markers and memory phenotype, as well as antigen spreading to personalized tumor antigens beyond the immunizing antigens.